Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
O75368
UPID:
SH3L1_HUMAN
Alternative names:
SH3 domain-binding glutamic acid-rich-like protein 1
Alternative UPACC:
O75368; Q3SYL1; Q5JT50; Q6FIE8; Q9H0N8
Background:
Adapter SH3BGRL, also known as SH3 domain-binding glutamic acid-rich-like protein 1, plays a crucial role in cellular processes. It acts as an adapter protein, facilitating interactions between proteins or proteins and mRNAs, as evidenced by research findings (PubMed:34331014). Furthermore, SH3BGRL is implicated in ubiquitin ligase-substrate adapter activity and associates with cytoplasmic ribosomes to enhance the expression of specific mRNAs (PubMed:34331014, PubMed:34870550).
Therapeutic significance:
Understanding the role of Adapter SH3BGRL could open doors to potential therapeutic strategies.